)
Clinically meaningful improvements in global IBS symptom severity observed as early as Week 1 and sustained through Week 7, with…
){kind=logo}
Phase 1b/2a study in cystic fibrosis remains on track for full enrollment by end of 2025 following positive interim analysis…
)
Kineticos Portfolio Company, Inceptor Bio, Announces First Patient Dosed in Clinical Trial of IB-T101 for Clear Cell Renal Cell Carcinoma…
Steve Gelone Joins Kineticos as a Strategic Advisor for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina –…
Lloyd Payne Joins Kineticos as Venture Partner for Kineticos AMR Accelerator Fund I (KAMRA I) Raleigh, North Carolina – January…
Clarametyx Biosciences Announces Investment by Kineticos AMR Accelerator Fund COLUMBUS, Ohio – January 28, 2025 – Clarametyx Biosciences Inc. (“Clarametyx”), a clinical…
INCATE and Kineticos extend partnership to support startups combating Antimicrobial Resistance December 16, 2024 – INCATE (the INCubator for Antibacterial Therapies…
Kineticos Portfolio Company Inceptor Bio Announces Strategic Partnership for Next-Generation Solid Tumor CAR-T December 18, 2024 –Inceptor Bio, a leading…